Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001034430 | SCV001197781 | likely benign | Developmental and epileptic encephalopathy 94 | 2022-11-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002337079 | SCV002643695 | uncertain significance | Inborn genetic diseases | 2018-11-12 | criteria provided, single submitter | clinical testing | The p.R1725Q variant (also known as c.5174G>A), located in coding exon 38 of the CHD2 gene, results from a G to A substitution at nucleotide position 5174. The arginine at codon 1725 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |